Effectiveness of piracetam in cortical myoclonus
Identifieur interne : 005D96 ( Main/Curation ); précédent : 005D95; suivant : 005D97Effectiveness of piracetam in cortical myoclonus
Auteurs : P. Brown [Royaume-Uni] ; M. J. Steiger [Royaume-Uni] ; P. D. Thompson [Royaume-Uni] ; J. C. Rothwell [Royaume-Uni] ; B. L. Day [Royaume-Uni] ; M. Salama [Belgique] ; T. Waegemans [Belgique] ; Marsden [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 1993.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Adult, Aged, Anticonvulsants (administration & dosage), Anticonvulsants (adverse effects), Cerebral Cortex (drug effects), Cerebral Cortex (physiopathology), Chemotherapy, Cortical myoclonus, Double-Blind Method, Drug Therapy, Combination, Electroencephalography (drug effects), Epilepsies, Myoclonic (drug therapy), Epilepsies, Myoclonic (physiopathology), Evoked Potentials, Somatosensory (drug effects), Evoked Potentials, Somatosensory (physiology), Female, Human, Humans, Male, Middle Aged, Myoclonus, Neurologic Examination (drug effects), Piracetam, Piracetam (administration & dosage), Piracetam (adverse effects), Treatment.
- MESH :
- chemical , administration & dosage : Anticonvulsants, Piracetam.
- chemical , adverse effects : Anticonvulsants, Piracetam.
- drug effects : Cerebral Cortex, Electroencephalography, Evoked Potentials, Somatosensory, Neurologic Examination.
- drug therapy : Epilepsies, Myoclonic.
- physiology : Evoked Potentials, Somatosensory.
- physiopathology : Cerebral Cortex, Epilepsies, Myoclonic.
- Adult, Aged, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged.
Abstract
Twenty‐one patients with disabling spontaneous, reflex, or action myoclonus due to various causes, who had shown apparent clinical improvement on introduction of piracetam, entered a placebo‐controlled double‐blind crossover trial of piracetam (2.4– 16.8 g daily). All but one patient had electrophysiological evidence of cortical myoclonus. Patients were randomly allocated to a 14‐ day course of piracetam followed by identical placebo, or placebo followed by piracetam. Nineteen patients received piracetam/placebo in addition to their routine antimyoclonic treatment (carbamazepine, clonazepam, phenytoin, primidone, sodium valproate, or tryptophan plus isocarboxazid, alone or in combination) and two received piracetam/placebo as monotherapy. All patients were rated at the end of each treatment phase using stimulus sensitivity, motor, writing, functional disability, global assessment, and visual analogue scales. Ten of the 21 patients had to be rescued from the placebo phase of the trial because of a severe and intolerable exacerbation of their myoclonus. No patients required rescue from the piracetam phase of the double‐blind trial. When the 21 patients were considered together, there was a significant improvement in motor, writing, functional disability, global assessment, and visual analogue scores during treatment with piracetam compared with placebo. The total rating score also improved significantly with piracetam, by a median of 22%. Piracetam, usually in combination with other antimyoclonic drugs, is a useful treatment for myoclonus of cortical origin.
Url:
DOI: 10.1002/mds.870080112
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001B54
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :001B54
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :004063
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004C70
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :004C70
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :004C60
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :004A01
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :004A01
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :004A01
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :009035
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003768
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :003056
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003732
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :009152
Links to Exploration step
ISTEX:BB6FBD1E67637226BCE673AD93997113E3721EBDLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effectiveness of piracetam in cortical myoclonus</title>
<author><name sortKey="Brown, P" sort="Brown, P" uniqKey="Brown P" first="P." last="Brown">P. Brown</name>
</author>
<author><name sortKey="Steiger, M J" sort="Steiger, M J" uniqKey="Steiger M" first="M. J." last="Steiger">M. J. Steiger</name>
</author>
<author><name sortKey="Thompson, P D" sort="Thompson, P D" uniqKey="Thompson P" first="P. D." last="Thompson">P. D. Thompson</name>
</author>
<author><name sortKey="Rothwell, J C" sort="Rothwell, J C" uniqKey="Rothwell J" first="J. C." last="Rothwell">J. C. Rothwell</name>
</author>
<author><name sortKey="Day, B L" sort="Day, B L" uniqKey="Day B" first="B. L." last="Day">B. L. Day</name>
</author>
<author><name sortKey="Salama, M" sort="Salama, M" uniqKey="Salama M" first="M." last="Salama">M. Salama</name>
</author>
<author><name sortKey="Waegemans, T" sort="Waegemans, T" uniqKey="Waegemans T" first="T." last="Waegemans">T. Waegemans</name>
</author>
<author><name sortKey="Marsden" sort="Marsden" uniqKey="Marsden" last="Marsden">Marsden</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:BB6FBD1E67637226BCE673AD93997113E3721EBD</idno>
<date when="1993" year="1993">1993</date>
<idno type="doi">10.1002/mds.870080112</idno>
<idno type="url">https://api.istex.fr/document/BB6FBD1E67637226BCE673AD93997113E3721EBD/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001B54</idno>
<idno type="wicri:Area/Istex/Curation">001B54</idno>
<idno type="wicri:Area/Istex/Checkpoint">004063</idno>
<idno type="wicri:doubleKey">0885-3185:1993:Brown P:effectiveness:of:piracetam</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:8419809</idno>
<idno type="wicri:Area/PubMed/Corpus">004C70</idno>
<idno type="wicri:Area/PubMed/Curation">004C70</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004C60</idno>
<idno type="wicri:Area/Ncbi/Merge">004A01</idno>
<idno type="wicri:Area/Ncbi/Curation">004A01</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004A01</idno>
<idno type="wicri:doubleKey">0885-3185:1993:Brown P:effectiveness:of:piracetam</idno>
<idno type="wicri:Area/Main/Merge">009035</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:93-0240361</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003768</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003056</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003732</idno>
<idno type="wicri:doubleKey">0885-3185:1993:Brown P:effectiveness:of:piracetam</idno>
<idno type="wicri:Area/Main/Merge">009152</idno>
<idno type="wicri:Area/Main/Curation">005D96</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effectiveness of piracetam in cortical myoclonus</title>
<author><name sortKey="Brown, P" sort="Brown, P" uniqKey="Brown P" first="P." last="Brown">P. Brown</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>MRC Human Movement and Balance Unit and University Department of Clinical Neurology, Institute of Neurology, London</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Steiger, M J" sort="Steiger, M J" uniqKey="Steiger M" first="M. J." last="Steiger">M. J. Steiger</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>MRC Human Movement and Balance Unit and University Department of Clinical Neurology, Institute of Neurology, London</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Thompson, P D" sort="Thompson, P D" uniqKey="Thompson P" first="P. D." last="Thompson">P. D. Thompson</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>MRC Human Movement and Balance Unit and University Department of Clinical Neurology, Institute of Neurology, London</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Rothwell, J C" sort="Rothwell, J C" uniqKey="Rothwell J" first="J. C." last="Rothwell">J. C. Rothwell</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>MRC Human Movement and Balance Unit and University Department of Clinical Neurology, Institute of Neurology, London</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Day, B L" sort="Day, B L" uniqKey="Day B" first="B. L." last="Day">B. L. Day</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>MRC Human Movement and Balance Unit and University Department of Clinical Neurology, Institute of Neurology, London</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Salama, M" sort="Salama, M" uniqKey="Salama M" first="M." last="Salama">M. Salama</name>
<affiliation wicri:level="1"><country xml:lang="fr">Belgique</country>
<wicri:regionArea>CRC, Brussels, Brainel 'Alleud</wicri:regionArea>
<wicri:noRegion>Brainel 'Alleud</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Waegemans, T" sort="Waegemans, T" uniqKey="Waegemans T" first="T." last="Waegemans">T. Waegemans</name>
<affiliation wicri:level="1"><country xml:lang="fr">Belgique</country>
<wicri:regionArea>U.C.B. s.a. Pharmaceutical Sector, Brainel 'Alleud</wicri:regionArea>
<wicri:noRegion>Brainel 'Alleud</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Marsden" sort="Marsden" uniqKey="Marsden" last="Marsden">Marsden</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>MRC Human Movement and Balance Unit and University Department of Clinical Neurology, Institute of Neurology, London</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1993">1993</date>
<biblScope unit="vol">8</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="63">63</biblScope>
<biblScope unit="page" to="68">68</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">BB6FBD1E67637226BCE673AD93997113E3721EBD</idno>
<idno type="DOI">10.1002/mds.870080112</idno>
<idno type="ArticleID">MDS870080112</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Anticonvulsants (administration & dosage)</term>
<term>Anticonvulsants (adverse effects)</term>
<term>Cerebral Cortex (drug effects)</term>
<term>Cerebral Cortex (physiopathology)</term>
<term>Chemotherapy</term>
<term>Cortical myoclonus</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Electroencephalography (drug effects)</term>
<term>Epilepsies, Myoclonic (drug therapy)</term>
<term>Epilepsies, Myoclonic (physiopathology)</term>
<term>Evoked Potentials, Somatosensory (drug effects)</term>
<term>Evoked Potentials, Somatosensory (physiology)</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Myoclonus</term>
<term>Neurologic Examination (drug effects)</term>
<term>Piracetam</term>
<term>Piracetam (administration & dosage)</term>
<term>Piracetam (adverse effects)</term>
<term>Treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anticonvulsants</term>
<term>Piracetam</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anticonvulsants</term>
<term>Piracetam</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cerebral Cortex</term>
<term>Electroencephalography</term>
<term>Evoked Potentials, Somatosensory</term>
<term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Epilepsies, Myoclonic</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Evoked Potentials, Somatosensory</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Cerebral Cortex</term>
<term>Epilepsies, Myoclonic</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Chimiothérapie</term>
<term>Homme</term>
<term>Myoclonie</term>
<term>Piracétam</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Twenty‐one patients with disabling spontaneous, reflex, or action myoclonus due to various causes, who had shown apparent clinical improvement on introduction of piracetam, entered a placebo‐controlled double‐blind crossover trial of piracetam (2.4– 16.8 g daily). All but one patient had electrophysiological evidence of cortical myoclonus. Patients were randomly allocated to a 14‐ day course of piracetam followed by identical placebo, or placebo followed by piracetam. Nineteen patients received piracetam/placebo in addition to their routine antimyoclonic treatment (carbamazepine, clonazepam, phenytoin, primidone, sodium valproate, or tryptophan plus isocarboxazid, alone or in combination) and two received piracetam/placebo as monotherapy. All patients were rated at the end of each treatment phase using stimulus sensitivity, motor, writing, functional disability, global assessment, and visual analogue scales. Ten of the 21 patients had to be rescued from the placebo phase of the trial because of a severe and intolerable exacerbation of their myoclonus. No patients required rescue from the piracetam phase of the double‐blind trial. When the 21 patients were considered together, there was a significant improvement in motor, writing, functional disability, global assessment, and visual analogue scores during treatment with piracetam compared with placebo. The total rating score also improved significantly with piracetam, by a median of 22%. Piracetam, usually in combination with other antimyoclonic drugs, is a useful treatment for myoclonus of cortical origin.</div>
</front>
</TEI>
<double idat="0885-3185:1993:Brown P:effectiveness:of:piracetam"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effectiveness of piracetam in cortical myoclonus</title>
<author><name sortKey="Brown, P" sort="Brown, P" uniqKey="Brown P" first="P." last="Brown">P. Brown</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>MRC, inst. neurology, human movement balance unit</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Steiger, M J" sort="Steiger, M J" uniqKey="Steiger M" first="M. J." last="Steiger">M. J. Steiger</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>MRC, inst. neurology, human movement balance unit</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Thompson, P D" sort="Thompson, P D" uniqKey="Thompson P" first="P. D." last="Thompson">P. D. Thompson</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>MRC, inst. neurology, human movement balance unit</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rothwell, J C" sort="Rothwell, J C" uniqKey="Rothwell J" first="J. C." last="Rothwell">J. C. Rothwell</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>MRC, inst. neurology, human movement balance unit</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Day, B L" sort="Day, B L" uniqKey="Day B" first="B. L." last="Day">B. L. Day</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>MRC, inst. neurology, human movement balance unit</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Salama, M" sort="Salama, M" uniqKey="Salama M" first="M." last="Salama">M. Salama</name>
</author>
<author><name sortKey="Waegemans, T" sort="Waegemans, T" uniqKey="Waegemans T" first="T." last="Waegemans">T. Waegemans</name>
</author>
<author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>MRC, inst. neurology, human movement balance unit</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">93-0240361</idno>
<date when="1993">1993</date>
<idno type="stanalyst">PASCAL 93-0240361 INIST</idno>
<idno type="RBID">Pascal:93-0240361</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003768</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003056</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003732</idno>
<idno type="wicri:doubleKey">0885-3185:1993:Brown P:effectiveness:of:piracetam</idno>
<idno type="wicri:Area/Main/Merge">009152</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effectiveness of piracetam in cortical myoclonus</title>
<author><name sortKey="Brown, P" sort="Brown, P" uniqKey="Brown P" first="P." last="Brown">P. Brown</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>MRC, inst. neurology, human movement balance unit</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Steiger, M J" sort="Steiger, M J" uniqKey="Steiger M" first="M. J." last="Steiger">M. J. Steiger</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>MRC, inst. neurology, human movement balance unit</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Thompson, P D" sort="Thompson, P D" uniqKey="Thompson P" first="P. D." last="Thompson">P. D. Thompson</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>MRC, inst. neurology, human movement balance unit</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rothwell, J C" sort="Rothwell, J C" uniqKey="Rothwell J" first="J. C." last="Rothwell">J. C. Rothwell</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>MRC, inst. neurology, human movement balance unit</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Day, B L" sort="Day, B L" uniqKey="Day B" first="B. L." last="Day">B. L. Day</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>MRC, inst. neurology, human movement balance unit</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Salama, M" sort="Salama, M" uniqKey="Salama M" first="M." last="Salama">M. Salama</name>
</author>
<author><name sortKey="Waegemans, T" sort="Waegemans, T" uniqKey="Waegemans T" first="T." last="Waegemans">T. Waegemans</name>
</author>
<author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>MRC, inst. neurology, human movement balance unit</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1993">1993</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chemotherapy</term>
<term>Human</term>
<term>Myoclonus</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Traitement</term>
<term>Homme</term>
<term>Chimiothérapie</term>
<term>Piracétam</term>
<term>Myoclonie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effectiveness of piracetam in cortical myoclonus</title>
<author><name sortKey="Brown, P" sort="Brown, P" uniqKey="Brown P" first="P." last="Brown">P. Brown</name>
</author>
<author><name sortKey="Steiger, M J" sort="Steiger, M J" uniqKey="Steiger M" first="M. J." last="Steiger">M. J. Steiger</name>
</author>
<author><name sortKey="Thompson, P D" sort="Thompson, P D" uniqKey="Thompson P" first="P. D." last="Thompson">P. D. Thompson</name>
</author>
<author><name sortKey="Rothwell, J C" sort="Rothwell, J C" uniqKey="Rothwell J" first="J. C." last="Rothwell">J. C. Rothwell</name>
</author>
<author><name sortKey="Day, B L" sort="Day, B L" uniqKey="Day B" first="B. L." last="Day">B. L. Day</name>
</author>
<author><name sortKey="Salama, M" sort="Salama, M" uniqKey="Salama M" first="M." last="Salama">M. Salama</name>
</author>
<author><name sortKey="Waegemans, T" sort="Waegemans, T" uniqKey="Waegemans T" first="T." last="Waegemans">T. Waegemans</name>
</author>
<author><name sortKey="Marsden" sort="Marsden" uniqKey="Marsden" last="Marsden">Marsden</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:BB6FBD1E67637226BCE673AD93997113E3721EBD</idno>
<date when="1993" year="1993">1993</date>
<idno type="doi">10.1002/mds.870080112</idno>
<idno type="url">https://api.istex.fr/document/BB6FBD1E67637226BCE673AD93997113E3721EBD/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001B54</idno>
<idno type="wicri:Area/Istex/Curation">001B54</idno>
<idno type="wicri:Area/Istex/Checkpoint">004063</idno>
<idno type="wicri:doubleKey">0885-3185:1993:Brown P:effectiveness:of:piracetam</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:8419809</idno>
<idno type="wicri:Area/PubMed/Corpus">004C70</idno>
<idno type="wicri:Area/PubMed/Curation">004C70</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004C60</idno>
<idno type="wicri:Area/Ncbi/Merge">004A01</idno>
<idno type="wicri:Area/Ncbi/Curation">004A01</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004A01</idno>
<idno type="wicri:doubleKey">0885-3185:1993:Brown P:effectiveness:of:piracetam</idno>
<idno type="wicri:Area/Main/Merge">009035</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effectiveness of piracetam in cortical myoclonus</title>
<author><name sortKey="Brown, P" sort="Brown, P" uniqKey="Brown P" first="P." last="Brown">P. Brown</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>MRC Human Movement and Balance Unit and University Department of Clinical Neurology, Institute of Neurology, London</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Steiger, M J" sort="Steiger, M J" uniqKey="Steiger M" first="M. J." last="Steiger">M. J. Steiger</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>MRC Human Movement and Balance Unit and University Department of Clinical Neurology, Institute of Neurology, London</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Thompson, P D" sort="Thompson, P D" uniqKey="Thompson P" first="P. D." last="Thompson">P. D. Thompson</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>MRC Human Movement and Balance Unit and University Department of Clinical Neurology, Institute of Neurology, London</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Rothwell, J C" sort="Rothwell, J C" uniqKey="Rothwell J" first="J. C." last="Rothwell">J. C. Rothwell</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>MRC Human Movement and Balance Unit and University Department of Clinical Neurology, Institute of Neurology, London</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Day, B L" sort="Day, B L" uniqKey="Day B" first="B. L." last="Day">B. L. Day</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>MRC Human Movement and Balance Unit and University Department of Clinical Neurology, Institute of Neurology, London</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Salama, M" sort="Salama, M" uniqKey="Salama M" first="M." last="Salama">M. Salama</name>
<affiliation wicri:level="1"><country xml:lang="fr">Belgique</country>
<wicri:regionArea>CRC, Brussels, Brainel 'Alleud</wicri:regionArea>
<wicri:noRegion>Brainel 'Alleud</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Waegemans, T" sort="Waegemans, T" uniqKey="Waegemans T" first="T." last="Waegemans">T. Waegemans</name>
<affiliation wicri:level="1"><country xml:lang="fr">Belgique</country>
<wicri:regionArea>U.C.B. s.a. Pharmaceutical Sector, Brainel 'Alleud</wicri:regionArea>
<wicri:noRegion>Brainel 'Alleud</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Marsden" sort="Marsden" uniqKey="Marsden" last="Marsden">Marsden</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>MRC Human Movement and Balance Unit and University Department of Clinical Neurology, Institute of Neurology, London</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1993">1993</date>
<biblScope unit="vol">8</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="63">63</biblScope>
<biblScope unit="page" to="68">68</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">BB6FBD1E67637226BCE673AD93997113E3721EBD</idno>
<idno type="DOI">10.1002/mds.870080112</idno>
<idno type="ArticleID">MDS870080112</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Anticonvulsants (administration & dosage)</term>
<term>Anticonvulsants (adverse effects)</term>
<term>Cerebral Cortex (drug effects)</term>
<term>Cerebral Cortex (physiopathology)</term>
<term>Cortical myoclonus</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Electroencephalography (drug effects)</term>
<term>Epilepsies, Myoclonic (drug therapy)</term>
<term>Epilepsies, Myoclonic (physiopathology)</term>
<term>Evoked Potentials, Somatosensory (drug effects)</term>
<term>Evoked Potentials, Somatosensory (physiology)</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neurologic Examination (drug effects)</term>
<term>Piracetam</term>
<term>Piracetam (administration & dosage)</term>
<term>Piracetam (adverse effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anticonvulsants</term>
<term>Piracetam</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anticonvulsants</term>
<term>Piracetam</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cerebral Cortex</term>
<term>Electroencephalography</term>
<term>Evoked Potentials, Somatosensory</term>
<term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Epilepsies, Myoclonic</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Evoked Potentials, Somatosensory</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Cerebral Cortex</term>
<term>Epilepsies, Myoclonic</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Twenty‐one patients with disabling spontaneous, reflex, or action myoclonus due to various causes, who had shown apparent clinical improvement on introduction of piracetam, entered a placebo‐controlled double‐blind crossover trial of piracetam (2.4– 16.8 g daily). All but one patient had electrophysiological evidence of cortical myoclonus. Patients were randomly allocated to a 14‐ day course of piracetam followed by identical placebo, or placebo followed by piracetam. Nineteen patients received piracetam/placebo in addition to their routine antimyoclonic treatment (carbamazepine, clonazepam, phenytoin, primidone, sodium valproate, or tryptophan plus isocarboxazid, alone or in combination) and two received piracetam/placebo as monotherapy. All patients were rated at the end of each treatment phase using stimulus sensitivity, motor, writing, functional disability, global assessment, and visual analogue scales. Ten of the 21 patients had to be rescued from the placebo phase of the trial because of a severe and intolerable exacerbation of their myoclonus. No patients required rescue from the piracetam phase of the double‐blind trial. When the 21 patients were considered together, there was a significant improvement in motor, writing, functional disability, global assessment, and visual analogue scores during treatment with piracetam compared with placebo. The total rating score also improved significantly with piracetam, by a median of 22%. Piracetam, usually in combination with other antimyoclonic drugs, is a useful treatment for myoclonus of cortical origin.</div>
</front>
</TEI>
</ISTEX>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005D96 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 005D96 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:BB6FBD1E67637226BCE673AD93997113E3721EBD |texte= Effectiveness of piracetam in cortical myoclonus }}
This area was generated with Dilib version V0.6.23. |